ABSTRACT

Introduction

Polatuzumab vedotin is an antibody–drug conjugate comprised of an anti-CD79b monoclonal antibody conjugated to monomethyl auristatin (MMAE), a microtubule-disrupting cytotoxin. CD79b is almost exclusively expressed on normal and malignant B-cells, making it an appealing target for novel therapeutics.

Areas covered

This article reviews the current literature on polatuzumab vedotin, including its pharmacology, as well as summarizing the results of clinical trials in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) as a single agent and in combination with other chemotherapies and chemoimmunotherapies. The current landscape of approved therapies for relapsed and refractory DLBCL, as well as other promising novel approaches, is discussed.

Expert opinion

The recent approval of polatuzumab vedotin in combination with bendamustine and rituximab (BR) offers another option to patients with DLBCL who are not eligible for autologous hematopoietic cell transplant or chimeric antigen receptors (CAR)-T cell therapy. In younger patients and those without serious comorbidities, polatuzumab vedotin-BR may serve as bridging therapy to more intensive therapies with reasonable efficacy and tolerability. Polatuzumab vedotin is currently being studied in a randomized trial in the front line setting in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).

中文翻译：

---

Polatuzumab vedotin 用于治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤

摘要

介绍

Polatuzumab vedotin 是一种抗体-药物偶联物，由与单甲基 auristatin (MMAE) 偶联的抗 CD79b 单克隆抗体组成，MMAE 是一种破坏微管的细胞毒素。CD79b 几乎只在正常和恶性 B 细胞上表达，使其成为新疗法的一个有吸引力的目标。

涵盖的领域

本文回顾了当前有关 polatuzumab vedotin 的文献，包括其药理学，并总结了复发/难治性弥漫性大 B 细胞淋巴瘤 (DLBCL) 作为单药和与其他化学疗法和化学免疫疗法联合使用的临床试验结果。讨论了目前已批准的复发性和难治性 DLBCL 疗法的前景，以及其他有希望的新方法。

专家意见

最近批准的 polatuzumab vedotin 联合苯达莫司汀和利妥昔单抗 (BR) 为不符合自体造血细胞移植或嵌合抗原受体 (CAR)-T 细胞治疗条件的 DLBCL 患者提供了另一种选择。在年轻患者和没有严重合并症的患者中，polatuzumab vedotin-BR 可作为具有合理疗效和耐受性的更强化疗法的桥接疗法。Polatuzumab vedotin 目前正在与利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松 (R-CHOP) 联合进行的一线随机试验中进行研究。